Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M |
| Total Depreciation and Amortization | 470.00M | 478.50M | 462.80M | 484.80M | 466.80M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.58B | -789.20M | 1.81B | -195.90M | 2.28B |
| Change in Net Operating Assets | 1.21B | -2.26B | -3.36B | -2.22B | -9.80M |
| Cash from Operations | 8.84B | 3.09B | 1.67B | 2.47B | 3.71B |
| Capital Expenditure | -2.09B | -1.70B | -1.51B | -1.50B | -1.35B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -549.40M | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -345.50M | -137.80M | -1.84B | -424.50M | -2.65B |
| Cash from Investing | -2.98B | -1.83B | -3.35B | -1.92B | -4.00B |
| Total Debt Issued | 6.71B | 0.00 | 6.46B | 0.00 | 4.96B |
| Total Debt Repaid | -4.09B | 824.70M | -1.85B | 3.04B | -3.09B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -708.10M | -692.20M | -1.20B | -2.05B | -446.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.35B | -1.35B | -1.35B | -1.17B | -1.17B |
| Other Financing Activities | -30.20M | -30.40M | -686.30M | -45.50M | -47.30M |
| Cash from Financing | 531.00M | -1.24B | 1.38B | -225.40M | 211.30M |
| Foreign Exchange rate Adjustments | 31.70M | 275.50M | 131.90M | -428.50M | 226.90M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.42B | 282.60M | -175.10M | -100.60M | 145.40M |